{"id":3403,"date":"2022-03-30T10:23:26","date_gmt":"2022-03-30T03:23:26","guid":{"rendered":"https:\/\/www.hivnat.org\/en\/?p=3403"},"modified":"2022-03-30T10:23:29","modified_gmt":"2022-03-30T03:23:29","slug":"a-phase-3-randomized-double-blind-study-to-evaluate-the-safety-and-efficacy-of-fixed-dose-combination-of-bictegravir-emtricitabine-tenofovir-alafenamide-versus-dolutegravir-emtricitabine-tenofovir","status":"publish","type":"post","link":"https:\/\/www.hivnat.org\/en\/studies\/3403\/","title":{"rendered":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine\/Tenofovir Disoproxil Fumarate in Treatment Na\u00efve, HIV-1 and Hepatitis B Co-Infected Adults"},"content":{"rendered":"\n<p>Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection. Integrase mutant viruses that are resistant to the INSTIs raltegravir (RAL) and elvitegravir (EVG) remain largely sensitive to bictegravir.\u00a0 Coformulated bictegravir with the NRTI emtricitabine (FTC; F) and the NtRTI tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once-daily use may provide a potent, convenient, tolerable, and practical regimen for the long-term treatment of patients with HBV and HIV co-infection. Therefore, this randomized, double-blind, multicenter, active-controlled study will evaluate the safety and efficacy of a FDC of B\/F\/TAF versus DTG + F\/TDF in HIV and HBV treatment-na\u00efve, HIV-1 and HBV coinfected adult subjects. Our site has contributed 1\/3 global enrollment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bictegravir (GS-9883) is a potent inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection. Integrase mutant viruses that are resistant to the INSTIs raltegravir (RAL)&hellip; <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-3403","post","type-post","status-publish","format-standard","hentry","category-studies"],"_links":{"self":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/3403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/comments?post=3403"}],"version-history":[{"count":1,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/3403\/revisions"}],"predecessor-version":[{"id":3404,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/posts\/3403\/revisions\/3404"}],"wp:attachment":[{"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/media?parent=3403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/categories?post=3403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hivnat.org\/en\/wp-json\/wp\/v2\/tags?post=3403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}